Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients

R. Centurioni, E. Bobbio-Pallavicini, C. Porta, F. Rodeghiero, L. Gugliotta, A. Billio, F. Tacconi, E. Ascari

Research output: Contribution to journalArticle

Abstract

Background. The experimental observation that plasma from TTP patients sometimes exhibits a protein which can cause platelet agglutination, and that such agglutination can be inhibited in vitro by the use of IgG led some authors to treat plasma exchange-resistant TTP patients with high-dose IgG (HDIgG). Methods. We report the results obtained with HDIgG treatment in 17 patients retrospectively examined by the Italian Cooperative Group for the study of TTP: 6 males and 11 females, mean age was 31.7 years for the women (range: 20-65) and 44.6 for the men (range: 26-66). In all cases HDIgG administration was combined with other treatment modalities. Results. Of the 17 patients, 7 died from disease progression (41.l%), 2 achieved partial remission (11.7%) and the remaining 8 achieved complete remission (47%). Of the 10 cases (58.8%) with a positive response, only in 4 did the addition of HDIgG seem to produce significant improvement. All efforts made to characterize the subgroup of patients who responded to HDIgG and compare them with the non responders failed. Conclusions. Although our results do not unquestionably demonstrate the role of HDIgG in the treatment of TTP, they suggest a possible role for HDIgG in the treatment of those rare plasma exchange-resistant TTP cases.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalHaematologica
Volume80
Issue number4
Publication statusPublished - 1995

Fingerprint

Thrombotic Thrombocytopenic Purpura
Immunoglobulins
Immunoglobulin G
Plasma Exchange
Agglutination
Therapeutics
Disease Progression
Blood Platelets
thymidine 5'-triphosphate

Keywords

  • high-dose immunoglobulins
  • salvage treatment
  • thrombotic thrombocytopenic purpura

ASJC Scopus subject areas

  • Hematology

Cite this

Centurioni, R., Bobbio-Pallavicini, E., Porta, C., Rodeghiero, F., Gugliotta, L., Billio, A., ... Ascari, E. (1995). Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Haematologica, 80(4), 325-331.

Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. / Centurioni, R.; Bobbio-Pallavicini, E.; Porta, C.; Rodeghiero, F.; Gugliotta, L.; Billio, A.; Tacconi, F.; Ascari, E.

In: Haematologica, Vol. 80, No. 4, 1995, p. 325-331.

Research output: Contribution to journalArticle

Centurioni, R, Bobbio-Pallavicini, E, Porta, C, Rodeghiero, F, Gugliotta, L, Billio, A, Tacconi, F & Ascari, E 1995, 'Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients', Haematologica, vol. 80, no. 4, pp. 325-331.
Centurioni R, Bobbio-Pallavicini E, Porta C, Rodeghiero F, Gugliotta L, Billio A et al. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Haematologica. 1995;80(4):325-331.
Centurioni, R. ; Bobbio-Pallavicini, E. ; Porta, C. ; Rodeghiero, F. ; Gugliotta, L. ; Billio, A. ; Tacconi, F. ; Ascari, E. / Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. In: Haematologica. 1995 ; Vol. 80, No. 4. pp. 325-331.
@article{06d6557301804792b7bd98267fb455e6,
title = "Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients",
abstract = "Background. The experimental observation that plasma from TTP patients sometimes exhibits a protein which can cause platelet agglutination, and that such agglutination can be inhibited in vitro by the use of IgG led some authors to treat plasma exchange-resistant TTP patients with high-dose IgG (HDIgG). Methods. We report the results obtained with HDIgG treatment in 17 patients retrospectively examined by the Italian Cooperative Group for the study of TTP: 6 males and 11 females, mean age was 31.7 years for the women (range: 20-65) and 44.6 for the men (range: 26-66). In all cases HDIgG administration was combined with other treatment modalities. Results. Of the 17 patients, 7 died from disease progression (41.l{\%}), 2 achieved partial remission (11.7{\%}) and the remaining 8 achieved complete remission (47{\%}). Of the 10 cases (58.8{\%}) with a positive response, only in 4 did the addition of HDIgG seem to produce significant improvement. All efforts made to characterize the subgroup of patients who responded to HDIgG and compare them with the non responders failed. Conclusions. Although our results do not unquestionably demonstrate the role of HDIgG in the treatment of TTP, they suggest a possible role for HDIgG in the treatment of those rare plasma exchange-resistant TTP cases.",
keywords = "high-dose immunoglobulins, salvage treatment, thrombotic thrombocytopenic purpura",
author = "R. Centurioni and E. Bobbio-Pallavicini and C. Porta and F. Rodeghiero and L. Gugliotta and A. Billio and F. Tacconi and E. Ascari",
year = "1995",
language = "English",
volume = "80",
pages = "325--331",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients

AU - Centurioni, R.

AU - Bobbio-Pallavicini, E.

AU - Porta, C.

AU - Rodeghiero, F.

AU - Gugliotta, L.

AU - Billio, A.

AU - Tacconi, F.

AU - Ascari, E.

PY - 1995

Y1 - 1995

N2 - Background. The experimental observation that plasma from TTP patients sometimes exhibits a protein which can cause platelet agglutination, and that such agglutination can be inhibited in vitro by the use of IgG led some authors to treat plasma exchange-resistant TTP patients with high-dose IgG (HDIgG). Methods. We report the results obtained with HDIgG treatment in 17 patients retrospectively examined by the Italian Cooperative Group for the study of TTP: 6 males and 11 females, mean age was 31.7 years for the women (range: 20-65) and 44.6 for the men (range: 26-66). In all cases HDIgG administration was combined with other treatment modalities. Results. Of the 17 patients, 7 died from disease progression (41.l%), 2 achieved partial remission (11.7%) and the remaining 8 achieved complete remission (47%). Of the 10 cases (58.8%) with a positive response, only in 4 did the addition of HDIgG seem to produce significant improvement. All efforts made to characterize the subgroup of patients who responded to HDIgG and compare them with the non responders failed. Conclusions. Although our results do not unquestionably demonstrate the role of HDIgG in the treatment of TTP, they suggest a possible role for HDIgG in the treatment of those rare plasma exchange-resistant TTP cases.

AB - Background. The experimental observation that plasma from TTP patients sometimes exhibits a protein which can cause platelet agglutination, and that such agglutination can be inhibited in vitro by the use of IgG led some authors to treat plasma exchange-resistant TTP patients with high-dose IgG (HDIgG). Methods. We report the results obtained with HDIgG treatment in 17 patients retrospectively examined by the Italian Cooperative Group for the study of TTP: 6 males and 11 females, mean age was 31.7 years for the women (range: 20-65) and 44.6 for the men (range: 26-66). In all cases HDIgG administration was combined with other treatment modalities. Results. Of the 17 patients, 7 died from disease progression (41.l%), 2 achieved partial remission (11.7%) and the remaining 8 achieved complete remission (47%). Of the 10 cases (58.8%) with a positive response, only in 4 did the addition of HDIgG seem to produce significant improvement. All efforts made to characterize the subgroup of patients who responded to HDIgG and compare them with the non responders failed. Conclusions. Although our results do not unquestionably demonstrate the role of HDIgG in the treatment of TTP, they suggest a possible role for HDIgG in the treatment of those rare plasma exchange-resistant TTP cases.

KW - high-dose immunoglobulins

KW - salvage treatment

KW - thrombotic thrombocytopenic purpura

UR - http://www.scopus.com/inward/record.url?scp=0029085424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029085424&partnerID=8YFLogxK

M3 - Article

C2 - 7590501

AN - SCOPUS:0029085424

VL - 80

SP - 325

EP - 331

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -